Download - Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

Transcript
Page 1: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

Biotech-Hotspot North Rhine-Westphalia

Busyness for Biotech.

BIO International Convention June 27-30, 2011 Washington D.C.

www.nrw-international.de

Page 2: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

PictureSource

n Cover: BIO.NRW, Max Planck Institute for Molecular Biomedicine;

University of Cologne Institute of Biochemistry

n Page 5: Düsseldorf Marketing & Tourismus

n Page 10-11: ATTO-TEC GmbH

n Page 12-13: Bayer Innovation

n Page 14-15: BioMedizinZentrum Dortmund

n Page 17: BIO.NRW; Max Planck Institute for

Molecular Biomedicine, Münster

n Page 19: CEVEC Pharmaceuticals GmbH

n Page 21: chemagen Biopolymer-Technologie AG

n Page 22-23: City of Düsseldorf – Office of Economic Development,

Düsseldorf Marketing & Tourismus GmbH

n Page 24-25: CLIB2021 Cluster Industrial Biotechnology

n Page 27: Cologne Bonn Business

n Page 29: Lead Discovery Center GmbH

n Page 30-31: Leibniz-Institut für Analytische Wissenschaften - ISAS

n Page 33: Miltenyi Biotec GmbH

n Page 35: NRW International

n Page 37: PAION AG

n Page 38-39: Syntab, Darren Baker - fotolia.com

Page 3: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

3

Content

Preface – Svenja Schulze ........................................................4

Greeting North Rhine-Westphalia ...........................................6

Overview – NRW Pavilion .........................................................8

NRW Program ...........................................................................9

Company Profiles

ATTO-TEC GmbH ...................................................................10

Bayer Innovation .................................................................... 12

BioMedizinZentrumDortmund ..............................................14

BIO.NRW Cluster Biotechnology North Rhine-Westphalia ...16

CEVEC Pharmaceuticals GmbH ............................................ 18

chemagen Biopolymer-Technologie AG .............................. 20

City of Düsseldorf – Office of Economic Development ...... 22

CLIB2021 Cluster Industrial Biotechnology ........................... 24

Cologne Bonn Business ........................................................ 26

Lead Discovery Center GmbH .............................................. 28

Leibniz-Institut für Analytische Wissenschaften - ISAS ...... 30

Miltenyi Biotec GmbH ........................................................... 32

NRW.International ................................................................. 34

PAION AG ............................................................................... 36

Syntab Therapeutics ............................................................. 38

Biotechnology Map of North Rhine-Westphalia ................. 40

Organisation / Sponsors .......................................................41

Page 4: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

North Rhine-Westphalia – We create opportunities!

North Rhine-Westphalia is Germany’s number one centre of chemical and pharmaceutical industry – with an increasing focus on sustainable economic development and the needs of the people. This includes an effective and efficient health sector and cutting-edge environment industries, plus innovative biotechnology which, as an interface technology with a vast potential for generating applications, is a mainstay of numerous industries in our state.

In North Rhine-Westphalia, some 70 university and non-university institutions and other scientific facilities are doing research in biotechnology and the life sciences.

In 2009 around 300 life science-related companies with 70 dedicated biotech companies (OECD definition) were located in North Rhine-Westphalia. According to the “OECD Biotechnological Statistics report”, North Rhine-Westphalia is Europe’s most innovative biotechnology region: It generates more biotech PCT patent applications than any other European region. Their economic impact is highlighted by the fact that more than 40 per cent of the overall German biotech turnover is generated in our state.

4

Preface

Svenja Schulze

Minister of Innovation, Science and Research

of the German State

of North Rhine-Westphalia

Page 5: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

5

We are putting an extra emphasis on creating the best possible framework for research and development, on sustainability, on better co-operation between academia and industry and on internationalization. We want to tap the full potential.

An example for this is the hosting of BioEurope in Düsseldorf, the North Rhine-Westphalia capital, in 2011. I’d like to invite you to visit this great event from 31st of October to 2nd of November 2011.

We look forward to welcome you at the BIO.NRW booth to meet innovative companies from North Rhine-Westphalia and contact partners for co-operation.

Svenja SchulzeMinister for Innovation, Science and Researchof the State of North Rhine-Westphalia

Page 6: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

6

Dear visitors and exhibitors,

The State of North Rhine-Westphalia (NRW) along with 12 companies and institutions is pleased to attend the BIO International Convention and to present the diversity and innovative potential of the biotech scene in NRW.

The largest German federal state North Rhine-Westphalia is situated at Europe’s geographic and economic center.In total, the state is home to more than 300 life science companies, among them 71 core biotechnology firms that together account for 42 % of German biotech turnover (according to the OECD definition). With 50 universities and research institutions conducting life science research, NRW also enjoys the highest concentration of academic institutions within Europe, as well as being Europe’s leading region when it comes to patenting biotech inventions.

One notable strength of NRW’s biotech industry is industrial (‘white’) biotechnology, which benefits from the state’s strong chemical industry. This sector is networked by the Cluster of Industrial Biotechnology, named CLIB2021.

The NRW events organized jointly by BIO.NRW and NRW.International at the German pavilion once again offer

Greeting

Dr. Bernward Garthoff

Chair of Cluster Biotechnology

North Rhine-Westphalia

Page 7: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

7

Almut Schmitz

CEO NRW.International

numerous opportunities to make contact with companies from Germany’s largest federal state. This brochure provides an initial overview of the companies’ products and services and invites you to visit our stand No. 2224 in Hall A. We wish you every success at the BIO International Convention 2011.

Dr. Bernward Garthoff Almut SchmitzChair of Cluster Biotechnology CEO NRW.InternationalNorth Rhine-Westphalia

Page 8: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

8

CLIB2021

2226

CEVEC2228

PAION2125

ISASInstitut

2127

Overview – NRW Pavilion

ATTO-TEC2230

chemagen2129

Further NRWrepresentatives:

Bayer Innovation

BioMedizinZentrumDortmund

City of Düsseldorf – Office of Economic Development

Cologne Bonn Business

Lead Discovery Center

Miltenyi Biotec

Syntab Therapeutics

NRW.International/ BIO.NRW

2224

Page 9: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

Program

Tuesday, June 28th

7.00 p.m. - 11.00 p.m.NRW Biotech Networking Reception

Venue: Hudson Restaurant and Lounge2030 M Street NW, Washington D.C.

MeetyourNorthRhine-Westphalianandinternationalbusinesspartnersanddecisionmakers.Enjoyafabulousnightwithfood,drinksandlivemusic.

RSVP:[email protected]

A shuttle bus will be provided directly from the BIO International Convention to the venue.

MeetingPoint: 6:30 p.m. at the BIO.NRW booth, 2224

Wednesday, June 29th

Novel opportunities and biotech solutions in the future health care market

Venue:Renaissance Washington, D.C. Downtown Hotel 999 Ninth Street NW, Washington, District of Columbia 20001

08:30a.m. Breakfast

ModerationBernwardGarthoff, BIO.NRWCluster Biotechnology NRW, Germany

09:00a.m.WelcomeAddressRichardGallagher, Chief Editor “Spotlight on Biotechnology”, San Francisco, USA

09:10a.m.HealthCareMarketoftheFuture:PerspectivesofbiotechsolutionsBillHuyett, Director McKinsey & Co., Boston, USA

09:40a.m.PlantMadePharmaceuticals:Avaccineforfollicularlymphoma JohnEdwardButler, Bayer Innovation GmbH, Düsseldorf, Germany, Dava Oncology LP, Dallas, USA

10:00a.m.Novel(stem-)cellbaseddiagnosticsandtherapeuticstowardsbedsideapplicationsKaiPinkernell, Head of Clinical Development, Miltenyi Biotec, Bergisch Gladbach, Germany

10:20a.m.PanelDiscussion

10:40a.m.End

Further NRWrepresentatives:

Bayer Innovation

BioMedizinZentrumDortmund

City of Düsseldorf – Office of Economic Development

Cologne Bonn Business

Lead Discovery Center

Miltenyi Biotec

Syntab Therapeutics

Page 10: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

10

ATTO-TEC GmbH

Am Eichenhang 50

57076 Siegen

+49-(0)271-238 530

+49-(0)271-238 5311

[email protected]

www.atto-tec.com

1999

14

Development and Synthesis of Fluorescent Dyes

ATTO-Dyes

ATTO Labels

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Technologies

Products

Fluorescence - What else?

Since the start up in 1999 ATTO-TEC is committed to being a first class provider of novel fluorescent labels that advance bioanalytical and biomedical research all over the world. More than 40 years of academic know-how were condensed into the company in order to develop innovative fluorescent solutions for the life science market. Science has always been a priority at ATTO-TEC. Our current staff brings together long-time expertise in dye chemistry and physics. We combine highest quality standards for all our products with an individualized customer support.

Page 11: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

11

ContactPersonattheBIOInternationalConvention

n Joerg Reichwein (CEO), [email protected]

n Jutta Arden-Jacob (R&D Manager), [email protected]

n Alexander Zilles (R&D Manager), [email protected]

Reseachers prefer ATTO-Labels for their high purity and excellent performance. In many applications our dyes are not merely an alternative, they are the better choice.

We are proud to present a new range of innovative fluorescent labels which show excitation and emission spectra that match all commonly used light sources and filters. It is a pleasure to introduce you to ATTO-TEC – the company that creates success with fluorescent dyes.

WhatwearelookingforattheBIOInternationalConvention

ATTO-TEC is looking for collaborations in the field of developing new fluorescent dyes and new products labeled with ATTO-Dyes which can be used for diagnostic and analytical detections.

Page 12: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

12

About Bayer Innovation GmbH and Icon Genetics

Bayer Innovation GmbH (BIG), a wholly owned subsidiary of Bayer AG, evaluates and develops new fields of business for the Bayer Group are related to Bayer’s core competencies of health care, nutrition and innovative materials and complement its current key areas of innovation and business.

Icon Genetics is a wholly owned subsidiary of Bayer Innovation GmbH; it was established in 1999 and acquired by Bayer in 2006. The company develops processes for the biotechnological production of proteins and other high-value products in plants.

Bayer:ScienceForABetterLifeBayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. The company’s products and services are designed to benefit people and improve their quality of life. At the same time Bayer creates value through innovation, growth and improved earning power. The Group is committed to the principles of sustainable development and acknowledges and accepts its role as a socially and ethically responsible “corporate citizen”. Economy, ecology and social

Bayer Innovation

Merowinger Platz 1

40225 Düsseldorf

+49-(0)211-758 458-38

+49-(0)271-758 458-73

[email protected]

www.bayer-innovation.de

2003

approx. 40

Personalized medicine, cancer vaccines, plasticulture, wound dressing

magnICON

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Technologies

Page 13: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

13

ContactPersonattheBIOInternationalConvention

n Dr. John Butler (Global Project Leader), [email protected]

responsibility are corporate policy objectives of equal rank. In fiscal 2007, Bayer employed 106,200 people and had sales of EUR 32.4 billion. Capital expenditures amounted to EUR 1.9 billion, the R&D budget to EUR 2.6 billion. More information is available on the Internet at www.bayer.com

WhatwearelookingforattheBIOInternationalConvention

Codevelopment partner autologous cancer vaccine

Page 14: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

14

The BioMedizinZentrumDortmund (BMZ)Your hub for innovative biotechnology

The biotech industry calls for coordinated business solutions. Product development within this area requires special laboratories with customized technical equipment. It is precisely here that the BMZ maintains cutting-edge infrastructures.

Dortmund–GatewaytotheFutureThe BMZ is located in the TechnologieParkDortmund in close proximity to the Technische Universität Dortmund,

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Otto-Hahn-Str. 15

44227 Dortmund

+49-(0)231-9742 164

+49-(0)231-9742 159

[email protected]

www.bmz-do.de

1984

50

Business incubation, start-up support

BioMedizinZentrumDortmund

Page 15: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

15

ContactPersonattheBIOInternationalConvention

n Andre van Hall (Head of BMZ), [email protected]

the Max Planck Institute of Molecular Physiology, the Leibniz-Institut für Analytische Wissenschaften (ISAS).

The local infrastructure provides an effective platform for technology transfer and the potential for close cooperation with the academic and business community.

The central location of Dortmund at the heart of the region’s health care industry also opens up excellent opportunities for high-end networking. Alongside its state-of-the-art research facilities, the site offers an extensive range of industrial properties, providing ample scope for the future growth of ambitious companies.

WhatwearelookingforattheBIOInternationalConvention

n Location marketing for the biotech region Dortmundn Attract new partners for the region Dortmundn Intensify collaboration with other biotech locations and networksn Supporting companies which are located within the BMZ

Page 16: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

16

BIO.NRW - Busyness for Biotech.

North Rhine-Westphalia’s biotechnology cluster BIO.NRW is a central catalyst for the sustainable development of the state’s biotech sector. It activates cooperation between business, research, investors and policy-makers. The cluster also promotes the strengths and achievements of biotechnology in the state: industrial biotechnology and pharmaceutical biotechnology.

BIO.NRW is part of an initiative by North Rhine-Westphalia’s (NRW) state government, which aims at making NRW the number one state for innovation. It has therefore established 16 technology clusters to systematically improve NRW’s strengths and talents in established industries and up-and-coming fields like biotechnology.

Goal of the “Excellence NRW” cluster strategy is to create a favourable climate for innovation, as that is the best way to sustain the competitive edge and stimulate growth and employment in the companies that call the state their home.

Servicesn Technology Transfern Support of Biotech Companies, esp. SMEn Support of Biotech Start-ups, Coaching & Financingn National and International Fairs, Exhibitions, and Conferences

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Merowingerplatz 1

40225 Düsseldorf

+49-(0)211-385469-9200

+49-(0)211-385469-9220

[email protected]

www.bio.nrw.de

2008

6

BIO.NRW Cluster Biotechnology North Rhine-Westphalia

Page 17: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

17

ContactPersonattheBIOInternationalConvention

n Annette Angenendt (PR & Marketing), [email protected]

n Dr. Bernward Garthoff (Chair of Cluster Biotechnology North

Rhine Westphalia), [email protected]

n Matthias Nerger (Head of office BIO.NRW), [email protected]

n Dr. Nils Schrader (Science Officer), [email protected]

n Analysis of biotechnology in North Rhine-Westphalia for location data

n Marketing & PR for the biotech state of North Rhine-Westphalia

n Promotion of young academics

WhatwearelookingforattheBIOInternationalConvention

n To showcase North-Rhine Westphalia’s strenghts in the Biotech Business

n Enabling NRW’s Biotech Companies and Institutions to pursue their business

n To foster targeted B2B Partneringn To seek and intensify international cooperationn To discuss the latest innovations in NRW

Page 18: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

18

Human Cells for Human Pharmaceuticals

CEVEC’s amniocyte derived protein expression technologies CAP and CAP-T are designed for stable and transient protein production. They achieve highest protein yields with authentic human glycosylation patterns. The versatile cells exhibit exceptional yields for antibodies and complex proteins and are also an excellent tool for vaccine/virus production.

The stable producer CAP cell line and the new transientCAP-T cell line meet all regulatory guidelines, are adopted to serum-free growth conditions and can be very efficiently transfected with commercially available transfection reagents. They are optimized to grow in a variety of flask/wave formats up to large-scale processing in bioreactors. Especially in the US the company is enjoying a broad and growing interest of pharma and biotech companies in employing the CAP and the CAP-T technology as the one and only cell expression system to be used from early discovery expression tasks (CAP-T) up to large-scale productionpurposes (CAP).

Gottfried-Hagen-Str. 62

51105 Cologne

+49-(0)221-460208 00

+49-(0)221-460208 01

[email protected]

www.cevec.com

2001

20

CAP Cell Technology – Human cell-based expression systems for

industrial use providing authentic human glycosylation patterns; one

platform for transient / stable cell line development for the production

of complex / difficult to express proteins and for the production of

vaccines and viruses. Custom cell line and process development service.

CAP-Technology

CAP, CAP-T

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Technologies

Products

CEVEC Pharmaceuticals GmbH

Page 19: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

19

ContactPersonattheBIOInternationalConvention

n Dr. Rainer Lichtenberger (CEO),

[email protected]

n Wolfgang Kintzel (Managing Director),

[email protected]

n Dr. Gudrun Schiedner (CSO),

[email protected]

n Gary J. Boch (Vice President Business Development,

North America), [email protected]

n Dr. Hartmut Tintrup (Director Marketing & Business Development)

[email protected]

WhatwearelookingforattheBIOInternationalConvention

CEVEC intends to attract additional potential customersby presenting the company and the benefits of CAP-Technology during partnering sessions. Based on recent

success regarding the use of CAP as a vaccine and virus production platform, the company also prepares foranother venture round with potential US participation.

Page 20: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

20

It‘s chemagic!

chemagen is a key player in the field of manual and automated nucleic acid isolation. chemagen’s kits and automation platforms facilitate DNA/RNA isolation from all clinical sample materials, such as blood, serum, plasma, urine, swabs, saliva, cells, etc.

chemagen’s high performance instrument is the chemagic Magnetic Separation Module I (chemagic MSM I) which can process 1 – 96 samples in one hour. It enables high throughput applications as well as large volume applications up to 10 ml. Combining the chemagic MSM I with a liquid handling unit enables a fully automated workflow from primary samples to e.g. PCR setup.

The chemagic Prepito, chemagen’s benchtop solution, facilitates the nucleic acid isolation of 1 - 12 samples from up to 1000 µl sample volume. Its integrated dispensing system reduces hands on time. The chemagic Prepito includes barcode reading to provide comfort and to support highest quality assurance demands.

chemagen Biopolymer-Technologie AG

Arnold-Sommerfeld-Ring 2

52499 Baesweiler

+49-(0)2401-805500

+49-(0)2401-805509

[email protected]

www.chemagen.com

1997

35

Magnetic Bead based nucleic acid isolation (automated and

manual), large scale protein purification

chemagic Separation Technology, M-PVA Magnetic Beads

chemagic Magnetic Separation Module I, chemagic Prepito,

chemagic Kits for nucleic acid isolation

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Technologies

Products

Page 21: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

21

ContactPersonattheBIOInternationalConvention

n Dr. Lothar à Brassard (CEO), [email protected]

Both automated systems use chemagen’s proprietary separation technology based on polyvinyl alcohol (PVA) Magnetic Beads. These Magnetic Beads are also available with different functionalities adapted to the customer’s needs.

The PVA Magnetic Beads are also applicable for high throughput protein purification and binds up to 1 g of the target protein. The large scale protein purification system facilitates applications such as Bio-Production and Bio-Separation.

Outstanding robustness, minimal hands-on time, fast and accurate performance – It´s chemagic!

WhatwearelookingforattheBIOInternationalConvention

Cooperation partners in the field of nucleic acid based diagnostics, and magnetic bead based applications.

Page 22: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

22

City of Düsseldorf Office of Economic Development

Supports life science companies situated in the Düsseldorf region, promotes the life science location Düsseldorf internationally and supports companies from North America and Asia in entering the European markets.

Burgplatz 1

40215 Düsseldorf

+49-(0)211-899 7688

+49-(0)211-893 7688

[email protected]

www.lifescience-dus.de

35

Economic Development

- Assists foreign companies in setting up their business in Düsseldorf

- Advises companies on permits and authorizations

- Procures industrial property, buildings, offices and laboratories

- Organizes financial assistance for young companies

Economic DevelopmentCity of Düsseldorf

City of Düsseldorf – Office of Economic Development

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Number of Employees

Areas of activity

Products

Page 23: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

23

ContactPersonattheBIOInternationalConvention

n Daniel Adler (Project Manager Life Science/Biotechnology),

[email protected]

The Office of Economic Development co-ordinates LifeScienceNet Düsseldorf, a powerful network of life science companies, universities, research institutions, public administration and biotech parks. As a focal point for life sciences, City of Düsseldorf is member of the BioRiver network, one of Germany’s TOP 4 biotech clusters.

WhatwearelookingforattheBIOInternationalConvention We are looking for companies that are thinking about expanding their business to Germany.

Page 24: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

24

CLIB2021 closes gaps between science & market

The Cluster CLIB2021 wants to establish industrial biotechnology within the chemical industry, small and mid-sized enterprises (SMEs) and in academia. It actively networks the chemical industry, biotechnology start-ups, SMEs and science institutes, customer industries and investors. CLIB2021 initiates future-oriented R&D

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Technologies

Collaborations

Products

Voelklingerstr. 4

40219 Düsseldorf

+49-(0)221-6793 141

+49-(0)221-6793 149

[email protected]

www.clib2021.de

2007

7

Industrial Biotechnology

Strain- and Enzym-Optimization, Bioprocesses,

Downstreaming, Bioproducts

Members network

Monomers, Skin Care, Enzymes, R&D Services

CLIB2021 Cluster Industrial Biotechnology

Page 25: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

25

ContactPersonattheBIOInternationalConvention

n Dr. Manfred Kircher (Chairman), [email protected]

projects in industrial biotechnology, strengthening the competitiveness of companies and academic institutes.

The organization supports start-up and project financing and provides expert advice. CLIB2021 has 84 members in Germany, Europe, North-America and Russia.

WhatwearelookingforattheBIOInternationalConvention

Industries, science institutes, governmental organizations and investors willing to partner in the field of industrial biotechnology.

Page 26: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

26

COLOGNE BONN BUSINESS The location marketing agency markets the Cologne Bonn Metropolitan Area

With almost 3.5 million inhabitants, the region is not only one of the most economically strong metropolitan areas in Germany, but also an attractive investment place for domestic and international investors.

To increase the awareness of this business region in thisinvestor-friendly environment, CBB highlights the followingpowerful industries: Automotive/Engineering,Chemistry, Finance/Insurance, Trade, Logistics, and Media & IT/Telecommunication. In addition, another major advantage of location is the region’s high skilled employees and executive managers in a demographic environment that does not threat at all. CBB is a union between the following local players: eight area municipalities, the saving banks, and the business initiative society of this business region.

Members of the company Standortmarketing Region Köln/Bonn GmbH, which was founded in 2003, are with 40% the business initiative society (Wirtschaftsinitiative Region Köln/Bonn e.V.), with 40% the society of the area municipalities (Verein Region Köln/Bonn e.V.), and with 20% the saving banks (Region Köln/Bonn Sparkassen

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Rheingasse 11

50676 Cologne

+49-(0)221-925 477 70

+49-(0)221-925 477 79

[email protected]

www.cologne-bonn-business.de

2003

6

International relations / national and international location marketing

Cologne Bonn Business

Page 27: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

27

ContactPersonattheBIOInternationalConvention

n Dr. Sylvia Knecht (CEO), [email protected]

n Carsten Weis (Project Manager & Public Relations ),

[email protected]

GbR). CEO of the division COLOGNE BONN BUSINESS of the company Standortmarketing Region Köln/Bonn GmbH is Dr. Sylvia Knecht.

WhatwearelookingforattheBIOInternationalConvention

The Cologne Bonn Metropolitan Area is characterized by an exciting mix of generations; from young, skilled workers, to qualified senior managers. Universities enjoy international reputation. This guarantees a high concentration of educational facilities and a high share of employees with a university education. Numerous patent applications are the indicator of intensive research being conducted. In the Cologne Bonn Metropolitan Area, the buying power per capita is above the national average. The right place for investments.

Page 28: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

28

Paving the way for innovative medicines

Founded in 2008, the recently announced research alliance with Merck KGaA and its first licensing deal with Bayer Schering Healthcare demonstrate that the Lead Discovery Center (LDC) efficiently acts as a translational link between excellent basic research and industry. Active in the field of pharmaceutical research, the LDC transforms promising early-stage projects into pharmaceutical leads being a prime source for external innovation. The LDC is committed to highest industrial quality standards for its Lead products. All leads offered for out-licensing come with proof-of-concept in animal models, solid IP protection and professional in-depth data packages, enabling a smooth transition into an industry partner’s lead optimization and drug development pipeline. Focusing on small molecules, the LDC conducts lead generation projects originating from academic groups as well as industry and sustains a preferred partnership with the Max Planck Society. Projects are developed in close collaboration with the project initiator who is generally one of the key opinion leaders in the respective field. The LDC offers core expertise in Cellular Biology, Assay Development

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Technologies

Collaborations

Products

Emil-Figge-Straße 76a

44227 Dortmund

+49-(0)2319-742 7000

+49-(0)2319-742 7039

[email protected]

www.lead-discovery.de

2008

44

Pharmaceutical Reasearch, early stages

Assay Development, Screening, Cellular Biology, ADME, Medicinal

Chemistry, Drug Discovery

Partners: Max-Planck-Institutes, Universities, Pharma

Customer: Pharma, Biotech, CRO (screening, ADME profiling etc.)

Leads according to highest industrial standards, Lead Optimisation

Lead Discovery Center GmbH

Page 29: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

29

& Screening, Pharmacology and Medicinal Chemistry. LDC has no indications limitation as projects benefit from the pathobiology know-how of its wide network into academia and clinic. The LDC team consist of industry-trained experts with solid experience in project management and drug

ContactPersonattheBIOInternationalConvention

n Thomas Hegendoerfer (Head of Business Development),

[email protected]

n Dr. Bert Klebl (Managing Director), [email protected]

discovery. Co-managing director Dr. Peter Nussbaumer spent more than 25 years with Novartis, co-managing director Dr. Bert Klebl has previously worked for Hoechst and Axxima among others.

WhatwearelookingforattheBIOInternationalConvention

n Licensing partners for novel Lead projects: • highly selective CDK7 inhibitors (oncology,

inflammation) • Axl kinase inhibitors (metastatic breast cancer)n Pharma partners interested in early partnering and risk

sharing models to access scientific excellence in drug discovery

Page 30: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

30

ISAS - Leading in Bioanalytics and Spectroscopy skills

ISAS is an independent physical and chemical analysis research institute, specialising in the fields of bioanalytics as well as material- and interface spectroscopy. The institute generates solutions for analytical problems, and to this end develops new or improved measuring principles and procedures, analytical techniques, methods and equipment. Since its foundation in 1952, the work of ISAS has been directed mainly towards user orientated basic research in the field of analytical chemistry.

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Technologies

Collaborations

Bunsen-Kirchhoff-Str. 11

44139 Dortmund

+49-(0)231-1392 0

+49-(0)231-1392 120

[email protected]

www.isas.de

1952

150

Research Institute

Bioanalytics, Material Analysis, Interface Spectroscopy, Proteomics

Technische Universität Dortmund, Technische Universität Berlin,

Ruhr-Universität Bochum

Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V.

Page 31: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

31

ContactPersonattheBIOInternationalConvention

n Tinka Wolf (Public relations officer), [email protected]

n Prof. Dr. Albert Sickmann (Director, Research area Bioanalytics),

[email protected]

The institute has gathered particular expertise in developing new methods and improving existing ones. To solve complex analytical problems various methods have been combined, according to the particular needs (the so-called multi-method concept). A few years ago, new expertise in the life sciences has extended the portfolio of the institute. Now ISAS combines skills in at least two state-of-the-art branches of modern sciences.

The main focus in the Bioanalytics department is the development of methods and procedures for fast and specific detection of proteins and their modifications in complex biological samples (e.g. cells, tissues and liquors). The scientists mainly focus on label free quantitative analytics of complex peptide or protein mixtures for the needs of systems biology.

WhatwearelookingforattheBIOInternationalConvention

We are looking especially for new cooperation partners for R&D projects, academic partners as well as partners from industry.

Page 32: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

32

Partners, taking you from basic research to clinical applications

Miltenyi Biotec, founded in 1989, is a premier provider of advanced products and services in the fields of stem cells, immune and cellular therapies as well as tissue regeneration. As a multinational corporation with more than 1100 employees in 18 countries worldwide, we develop, manufacture and commercialize state-of the-art technologies and products for research and clinical applications. Our product and service offerings cover all areas of cell-based research and clinical development, from sample preparation, cell separation, cell culture, flow cytometric and molecular analysis, including gene expression profiling and DNA analysis, to clinical therapeutic applications and contract GMP manufacturing.

Friedrich-Ebert-Str. 68

51429 Bergisch Gladbach

+49-(0)2204-83060

+49-(0)2204-85197

[email protected]

www.miltenyibiotec.com

1989

1190

Stem cells, immune and cellular therapies, tissue regeneration,

immunology, contract manufacturing, customisation and

development services

- Magnetic cell separation for research and clinical use

- Automated sample preparation for a) generation of single cell

suspension, b) rare cell analysis, c) protein analysis and

d) nucleic acid analysis

- Flow Cytometry Platform, Therapeutic apharesis

gentleMACS™ Dissociator, autoMACS™ Pro Separator,

MACSQuant® Analyzer, MACS® Cell Culture Media & Reagents,

cryoMACS® Freezing bags, CliniMACS®plus System,

CliniMACS® Prodigy System

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Technologies

Products

Miltenyi Biotec GmbH

Page 33: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

33

ContactPersonattheBIOInternationalConvention

n Dr. Oliver Bartelsen (Global Head Business Development),

[email protected]

n Dr. Uwe Janssen (Business Development Manager),

[email protected]

n Brian Wendelburg, Ph.D. (Business Development Manager, U.S.),

[email protected]

Our research tools, analytical and preparative instruments, clinical-grade reagents and medical devices provide integrated translational solutions that meet the high demands and expectations that Miltenyi Biotec customers have come to expect from a leading biotechnology tool provider

WhatwearelookingforattheBIOInternationalConvention

n Collaboration partners in the areas of stem cells, immune and cellular therapies, tissue regeneration, immunology

n Innovative technologies and reagents for sample preparation, cell separation, cell analysis

n Customers for Genomic Services and Contract Manufacturing Services

Page 34: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

34

NRW.International – Export-Promotion for North Rhine-WestphaliaYour partner for industry in the development of growth markets

NRW.International coordinates the promotion of foreign trade in North Rhine-Westphalia. In particular, it supports small and medium-sized enterprises in the development of important growth markets worldwide. It is sponsored by the chambers of commerce and industry in North Rhine-Westphalia, the state’s chambers of crafts and NRW.BANK. The projects are subsidized by the NRW Ministry for Economic Affairs, Energy, Building, Housing and Transport.

The primary objective is to gear the instruments and activities of foreign trade promotion to the requirements of industry. In close coordination with its partners in chambers of commerce and industry, chambers of crafts, economic development agencies, associations, clusters and state initiatives, NRW.International provides a variety of measures tailored to the companies’ needs:

Participation in trade fairs abroad – Companies can present their products and services to a broad audience of trade professionals as part of joint company stands, information service centers or small groups.

Voelklingerstr. 4

40219 Düsseldorf

+49-(0)211-71067 112

+49-(0)211-71067 120

[email protected]

www.nrw-international.de

2006

10

Export promotion for SMEs from North Rhine-Westphalia

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

NRW.International

Page 35: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

35

ContactPersonattheBIOInternationalConvention

n Bety Chu (Head of International Trade Fairs),

[email protected]

Delegation and entrepreneur trips – Together with its partners, NRW.International organizes and coordinates trips for delegations and entrepreneurs. In keeping with the development and growth potential in the target markets concerned, these activities are accompanied politically by the state government.

Other services – Industry information and cooperation events within the framework of trade fairs or delegation trips round off the services of NRW.International.

Numerous consulting sessions and information events offered by the partners provide companies with additional assistance in establishing and expanding their foreign business. In this way the services are tailored optimally to the needs of the companies and guarantee the efficient and business-friendly promotion of foreign trade.

Page 36: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

36

The PAION Principle

PAION AG is a biopharmaceutical company focusing on the clinical development of drug candidates for diseases or interventions for which there is a substantial unmet medical need.

After proof of concept in humans – the greatest value creating step prior to market approval – the strategy is to out-license or co-develop the drug candidates with pharma partners.

PAION further profits from the receipt of payments for reaching clinical and commercial milestones and receiving royalties after market approval of the drugs. Further upside can be generated from co-commercialisation activities.

With this business model revenues can be generated at an early stage, decreasing development costs and risks.

With currently two development programmes in Phase II , one programme has completed Phase II and two programmes in Phase I, PAION is excellently positioned.

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Collaborations

Products

Martinstrasse 10-12

52062 Aachen

+49-(0)241-4453 0

+49-(0)241-4453 100

[email protected]

www.paion.com

2000

27

Clinical development of drug candidates for diseases or interventions

for which there is a substantial unmet medical need.

H. Lundbeck A/S, Ono Pharmaceutical Co., Ltd., Acorda

Therapeutics, Inc., Bayer Schering Pharma AG

Remimazolam, Desmoteplase, M6G, Solulin, GGF2

PAION AG

Page 37: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

37

ContactPersonattheBIOInternationalConvention

n Ralf Penner (Director Investor Relations/Public Realtions),

[email protected]

n Richard Middleton (Vice President Business Development),

[email protected]

WhatwearelookingforattheBIOInternationalConvention

PAION intends to expand its portfolio of drug candidates and strives to cooperate with experienced partners, particularly during the later stages of clinical development,

regulatory procedures and commercialisation. Due to the recent development progress with Solulin PAION is seeking Partners to develop Solulin in Haemophilia and/or Radiation Injury. For Remimazolam and M6G availability of regional rights is subject to ongoing partnering discussions. PAION is interested in late stage to approved projects ideally in the anaesthesiology or critical care environment.

Page 38: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

38

Small, simple and specific: synthetic antibodies

Syntab Therapeutics is doing research and development of innovative pharmaceuticals. The company owns a proprietary technology platform for the development and production of synthetic antibodies. In early 2011, Syntab

Address/P.O. Box

Postal Code/City

Telephone

Fax

Email Address

Website

Founded (year)

Number of Employees

Areas of activity

Collaborations

Products

Dennewartstrasse 25-27

52068 Aachen

+49-(0)241-963 1555

+49-(0)241-963 1559

[email protected]

www.syntab-therapeutics.com

2010

< 10

Drug Development

are very welcome. Syntab Therapeutics has already established a

number of contacts to academic and business partners in order to

ensure efficiency in clinical development and short time-to-market.

Syntab Therapeutics’ lead synthetic antibody candidate, SAB-Y1,

is applied in cancer therapy. It is yet in preclinical development. Its

molecular target is the epidermal growth factor receptor (EGFR).

Syntab Therapeutics

Page 39: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

39

ContactPersonattheBIOInternationalConvention

n Ute Steinbusch (Scientific Coordinator),

[email protected]

Therapeutics received a grant from the German ministry of education and research in order to validate the synthetic antibody concept within the upcoming 3 years.

The technology platform enables the company to synthesize highly effective drugs against cancer and other

types of diseases. These drugs show the positive effects of monoclonal antibodies (high specificity for the target molecule, activation of the immune system), but they are much smaller and simpler in manufacturing.

WhatwearelookingforattheBIOInternationalConvention

Syntab Therapeutics is focussed on preclinical development of its drug candidates. We are interested in finding pharma partners that can ensure the effective further clinical development and marketing.

Page 40: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

40

Biotechnology Map of North Rhine-Westphalia

MünsterQ

Q Dortmund

Q Bielefeld

Q

Bonn

Duisburg Q

Q Cologne

Q Nettetal Q Witten

Q Gronau

Q

Bochum

Q Wuppertal

Q Hilden

Q Juelich

Q

Essen

Q Düsseldorf

Q Marl

Monheim QQ Leverkusen

Q Leopoldshöhe

Q Langenfeld

Herzogenrath Q Q Baesweiler

Q Troisdorf

Q

Westerkappeln

Q Aachen

Q Rheda-Wiedenbrück

Page 41: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

41

aprojectof

NRW International GmbHVölklinger Str. 4, 40219 Düsseldorf Phone: +49-(0)211-71 06 71 10Fax: +49-(0)211-71 06 71 [email protected]

sponsoredby

Ministry of Economic Affairs, Energy, Building, Housing and Transport of the State of North Rhine-WestphaliaHaroldstr. 4, 40213 DüsseldorfPhone: +49-(0)211-83 70 2Fax: +49-(0)211-83 72 20 [email protected]

Ministry of Innovation, Scienceand Research of the State of North Rhine-WestphaliaVölklinger Str. 49, 40221 DüsseldorfPhone: +49-(0)211-89 60 4Fax: +49-(0)211-89 64 55 [email protected]

incooperationwith

BIO.NRWMerowingerplatz 1, 40225 DüsseldorfPhone: +49-(0)211-38 54 69 92 00Fax: +49-(0)211-38 54 69 92 [email protected]

organisedby

LMI Leipziger Messe International GmbHMesse-Allee 1, 04356 LeipzigPhone: +49-(0)341-678 7900Fax: +49-(0)341 678 [email protected]

Organisation / Sponsors

Page 42: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

42

Notes

Page 43: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech
Page 44: Biotech-Hotspot North Rhine-Westphalia Busyness for Biotech

NRW.International GmbH

Voelklinger Straße 4

40219 Düsseldorf/Germany

Phone: +49-211 710671-10

Fax: +49-211 710671-20

E-Mail: [email protected]

www.nrw-international.de